| Identification | Back Directory | [Name]
Propanoic acid, 3-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]oxy]ethoxy]ethoxy]- | [CAS]
2682112-08-7 | [Synonyms]
Thalidomide-5-PEG3-COOH
3-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)oxy)ethoxy)ethoxy)propanoic acid
Propanoic acid, 3-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]oxy]ethoxy]ethoxy]- | [Molecular Formula]
C20H22N2O9 | [MOL File]
2682112-08-7.mol | [Molecular Weight]
434.4 |
| Chemical Properties | Back Directory | [Boiling point ]
717.1±60.0 °C(Predicted) | [density ]
1.437±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
4.27±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. | [IC 50]
Cereblon | [References]
[1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-987. DOI:10.1016/j.envpol.2020.115334 |
|
|